Decoding the transcriptome

A platform for drug discovery in RNA biology

Scaffold Therapeutics is advancing a unique pipeline of assets targeting clinically validated and first in class biology in oncology, neurodegeneration and other therapeutic areas

Our research is focused on regulating modifications of RNA that control its stability, transcription and degradation.


Management Team

Jeff Carter


Rene Lemieux, PhD


Jeff Hixon

Strategy and Operations

Francesco Salituro, PhD

Head of Drug Discovery

Board and Advisors

Wasim Malik, PhD

Board Member

Kathleen Burns, MD, PhD

Clinical Advisor

Eytan Stein, MD

Clinical Advisor

Stuart Chaffee, PhD

Business Advisor

Yadira Soto-Feliciano, PhD

Scientific Advisor

Amedeo Caflisch, PhD

Academic Collaborator and Advisor

Now partnered with QureALZ!

Scaffold Therapeutics has partnered with QureALZ - a company dedicated to sponsoring breakthrough research on Alzheimer's and other neurodegenerative disorders. This partnership will leverage Scaffold's drug discovery platform and world class drug discovery team to advance research into a range of diseases from Alzheimer's disease to ALS to brain cancer.